Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.annder.2008.10.044 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A review on toxic epidermal necrolysis-like superficial wound lesions: Issue and challenge on 10 clinical entities.
Int Wound J
December 2024
Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran.
Toxic epidermal necrolysis (TEN) is a severe skin reaction caused by extensive epidermal and mucosal necrosis. This clinical phenomenon is known as an acute syndrome of apoptotic pan-epidermolysis (ASAP). The ASAP phenomenon is observed in conditions that mimic TEN, highlighting the challenge in distinguishing these conditions.
View Article and Find Full Text PDFFactors Influencing the Clinical Course of Bullous Pemphigoid among Geriatric Patients: A Pilot Study.
Medicina (Kaunas)
October 2024
Department of Dermatology, Pediatric Dermatology and Oncology, Medical University of Lodz, 90-419 Lodz, Poland.
: Bullous pemphigoid (BP) is the most common autoimmune blistering disease affecting mainly elderly patients. Still, little is known about the pathogenesis of pruritus in BP or the factors that affect the clinical course of the disease. This study aimed to evaluate the factors influencing the clinical course of BP among older patients.
View Article and Find Full Text PDFImpact of postoperative intraocular pressure elevation on graft endothelial cells in non-preexisting glaucoma eyes undergoing descemet membrane endothelial keratoplasty: a cohort study.
BMC Ophthalmol
October 2024
Department of Ophthalmology, Peking University Third Hospital, No. 49 Garden North Road, Haidian District, Beijing, 100191, People's Republic of China.
Background: Descemet membrane endothelial keratoplasty (DMEK) has become the dominant keratoplasty procedure. However, the impact of high intraocular pressure (IOP) on the DMEK prognosis in patients without preexisting glaucoma remains unknown.
Methods: Non-glaucoma patients who underwent DMEK in Peking University Third Hospital between July 2017 and March 2023 with a follow-up duration longer than six months were included in this cohort study.
Pathophysiology of Bullous Pemphigoid: Role of Type 2 Inflammation and Emerging Treatment Strategies (Narrative Review).
Adv Ther
December 2024
Sanofi, Cambridge, MA, USA.
Article Synopsis
- Bullous pemphigoid (BP) is an autoimmune blistering disease mainly seen in older adults, significantly affecting their quality of life.
- The disease involves autoantibodies against specific proteins and displays characteristics of type 2 inflammation, including high levels of IgE and eosinophils, along with increased type 2 cytokines in skin lesions.
- This review highlights the pathophysiology of BP, the impact of biologics targeting type 2 immune mediators, and the potential for future targeted therapies to improve treatment options.
Comprehensive combined analysis of physician-initiated phase II and III clinical trials on a cultured human corneal endothelial cell product for treating bullous keratopathy.
Jpn J Ophthalmol
November 2024
Department of Frontier Medical Science and Technology for Ophthalmology, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Hirokoji-agaru, Kawaramachi-dori, Kamigyo-ku, Kyoto, 602-0841, Japan.
Article Synopsis
- A study evaluated the effectiveness and safety of cultured human corneal endothelial cells (cHCEC) for treating bullous keratopathy (BK) across phase II and III clinical trials involving 27 patients.
- The primary goal was to achieve a corneal endothelial cell density of at least 1000 cells/mm by 24 weeks post-transplant, which was successful in 94.1% of cases, alongside significant reductions in corneal thickness and improvements in vision.
- While 88.9% of patients experienced mild and temporary adverse events, the cHCEC treatment showed promising results in restoring corneal function and visual acuity.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!